000277436 001__ 277436
000277436 005__ 20240229155017.0
000277436 0247_ $$2doi$$a10.1016/j.clnu.2023.06.028
000277436 0247_ $$2pmid$$apmid:37421851
000277436 0247_ $$2ISSN$$a0261-5614
000277436 0247_ $$2ISSN$$a1532-1983
000277436 0247_ $$2altmetric$$aaltmetric:150999735
000277436 037__ $$aDKFZ-2023-01373
000277436 041__ $$aEnglish
000277436 082__ $$a610
000277436 1001_ $$aZhang, Haifeng$$b0
000277436 245__ $$aAssociation between intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid (n-3 PUFA DHA) and reduced risk of ovarian cancer: A systematic Mendelian Randomization study.
000277436 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000277436 3367_ $$2DRIVER$$aarticle
000277436 3367_ $$2DataCite$$aOutput Types/Journal article
000277436 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688995896_5077
000277436 3367_ $$2BibTeX$$aARTICLE
000277436 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277436 3367_ $$00$$2EndNote$$aJournal Article
000277436 520__ $$aWhether the intake of docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, is beneficial for ovarian cancer (OC) remains controversial and we hope to disentangle this puzzle using genetic data from large-scale populations in European and Asian.We employed, for the first time, a systematic Mendelian randomization (MR) design to comprehensively evaluate the causal effect of plasma DHA levels, an objective biomarker of DHA intake, on OC risk in European and then verified the extrapolation of the results in the Asian. Data in the analysis included genetic association data obtained from large-scale genome-wide association studies with 13,499 individuals for plasma DHA measurements and 66,450 individuals for OC in the European population, and 1361 individuals for plasma DHA measurements and 61,457 individuals for OC in the Asian population. The causal relationship between DHA and OC was estimated using the inverse-variance weighted approach, together with extensive validation and sensitivity analyses to verify the main results.In the European population, MR evidence suggested a causal relationship between higher plasma DHA levels and lower OC risk (OR, 0.89 for OC per one-SD increment in DHA; 95% CI, 0.83 to 0.96; P = 0.003). Subgroup analysis by histological type of OC indicated that this observed association was stronger among endometrioid ovarian cancer (EOC) (OR, 0.82; 95% CI, 0.69 to 0.96; P = 0.014). A similar causal association of borderline significance was reached in the Asian replication set. The above results were consistently supported by a series of validation and sensitivity analyses.Our study provided robust genetic evidence for a protective association between plasma DHA levels and lower risk of OC, especially EOC, in the European population. These findings may inform prevention strategies and interventions directed towards DHA intake and OC.
000277436 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277436 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277436 650_7 $$2Other$$aDocosahexaenoic acid (DHA)
000277436 650_7 $$2Other$$aGenome-wide association study (GWAS)
000277436 650_7 $$2Other$$aMendelian randomization (MR)
000277436 650_7 $$2Other$$aOvarian cancer
000277436 650_7 $$2Other$$an-3 polyunsaturated fatty acid (PUFA)
000277436 7001_ $$aYao, Yinshuang$$b1
000277436 7001_ $$aZhong, Xiaoyan$$b2
000277436 7001_ $$aMeng, Fang$$b3
000277436 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$udkfz
000277436 7001_ $$aQiu, Junlan$$b5
000277436 7001_ $$aShu, Xiaochen$$b6
000277436 773__ $$0PERI:(DE-600)2009052-3$$a10.1016/j.clnu.2023.06.028$$gVol. 42, no. 8, p. 1379 - 1388$$n8$$p1379 - 1388$$tClinical nutrition$$v42$$x0261-5614$$y2023
000277436 909CO $$ooai:inrepo02.dkfz.de:277436$$pVDB
000277436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000277436 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277436 9141_ $$y2023
000277436 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000277436 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000277436 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-28$$wger
000277436 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN NUTR : 2022$$d2023-08-28
000277436 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000277436 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000277436 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000277436 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000277436 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-28
000277436 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN NUTR : 2022$$d2023-08-28
000277436 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277436 980__ $$ajournal
000277436 980__ $$aVDB
000277436 980__ $$aI:(DE-He78)C020-20160331
000277436 980__ $$aUNRESTRICTED